Reduces elevated intraocular pressure (IOP). ANDA 220360, held by Mankind Pharma. Latanoprost.
As of Nov 15, 2026, ANDA 220360 (Latanoprost), held by Mankind Pharma, was first approved by FDA on Dec 17, 2025, with 0 approved supplements and 0 published complete response letters.
Latanoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 17, 2025 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Latanoprost0.005% · solution/drops;ophthalmic | Latanoprost | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
